AI-guided redesign of protein alphabet in bacteria could unlock new ways to build synthetic organisms.
In a notable shift in investment sentiment, Replimune Group, Inc. (NASDAQ: REPL) received a “Hold” rating from Roger Song of Jefferies on April 13, 2026. With the stock currently priced at $4.76, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results